“DNA-Guided” Therapy

  • Nicola Carlomagno
  • Luigi Pelosio
  • Akbar Jamshidi
  • Francesca Duraturo
  • Paola Izzo
  • Andrea Renda
Part of the Updates in Surgery book series (UPDATESSURG)


Rapid progress in understanding the biomolecular basis of disease has brought new concepts to the diagnosis and treatment of some hereditary tumors. After the genes causing the syndromes were identified, the first step was the adoption of predictive genetic tests to identify within affected families those subjects considered to be carriers of the mutations, and then to enroll them in intensive surveillance program and perhaps even to offer prophylactic therapy. Over the years, and particularly following the detection of many types of alterations in the genes responsible for hereditary tumors, it has become possible to correlate genotype, as determined by genetic testing, with the heterogeneous forms of phenotypic expression and clinical manifestations, and thus to provide patients with prognostic information.


Ovarian Cancer Lynch Syndrome Medullary Thyroid Carcinoma Multiple Endocrine Neoplasia Type Medullary Thyroid Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bodmer WF, Bailey CJ, Bodmer J et al (1987) Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328:614–16PubMedCrossRefGoogle Scholar
  2. 2.
    Groden J, Thliveris A, Samowitz W (1991) Identification of the gene for familial adenomatous coli gene. Cell 66:589–600PubMedCrossRefGoogle Scholar
  3. 3.
    Renda A, Izzo P, Carlomagno N et al (1997) Implicazioni cliniche delle conoscenze molecolari nei tumori eredofamiliari del colon-retto. Atti 99° Congresso Nazionale Società Italiana di Chirurgia. Pozzi, RomeGoogle Scholar
  4. 4.
    Leite JS, Isidro G, Martins M et al (2005) Is prophylactic colectomy indicated in patients with MYH-associated polyposis? Colorectal Dis 7:327–331PubMedCrossRefGoogle Scholar
  5. 5.
    Vasen HFA (1991) The international collaborative Group on Hereditary non-polyposis colorectal cancer. Dis Col Rectum 34:425–425CrossRefGoogle Scholar
  6. 6.
    Rodriguez-Bigas MA, Boland CR, Hamilton SR et al (1997) A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762PubMedCrossRefGoogle Scholar
  7. 7.
    Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedGoogle Scholar
  8. 8.
    Vasen HF, Watson P, Mecklin JP, Lynch HAT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456PubMedCrossRefGoogle Scholar
  9. 9.
    Peterson G (1999) Genetic testings for cancer: the surgeon’s critical role. Clinical cancer genetics: 1998 (what’s available to you in your practice). J Am Coll Surg 188(1):89–93PubMedGoogle Scholar
  10. 10.
    Batra S, Valdimarsdottir H, McGovern M et al (2002) Awareness of genetic testing for colorectal cancer predisposition among specialists in gastroenterology. Am J Gastroenterol 97(3):729–733PubMedCrossRefGoogle Scholar
  11. 11.
    Schroy PC, Barrison AF, Ling BS et al (2002) Family history and colorectal cancer screening: a survey of physician knowledge and practice patterns. Am J Gastroenterol 97:1031–1036PubMedCrossRefGoogle Scholar
  12. 12.
    Schroy Lynch HT, Lynch JF (2000) Hereditary nonpolyposis colorectal cancer. Semin Surg Oncol 18(4):305–313CrossRefGoogle Scholar
  13. 13.
    Jarvinen HJ (1995) Screening reduces colorectal cancer rates in families with hereditary non-polyposis colorectal cancer. Gastroenterology 108:1405–1411PubMedCrossRefGoogle Scholar
  14. 14.
    de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al (2002) Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45:1588–1594CrossRefGoogle Scholar
  15. 15.
    Scacheri PC, Davis S, Odom DT et al (2006) Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet 2(4): e51. DOI:10.1371/journal.pgen.0020051PubMedCrossRefGoogle Scholar
  16. 16.
    Geerdink EAM, Van der Luijt1 RB, Lips CJM (2003) Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 149:577–582PubMedCrossRefGoogle Scholar
  17. 17.
    Schussheim DH, Skarulis MC, Agarwal SK et al (2001) Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 12:173–178PubMedCrossRefGoogle Scholar
  18. 18.
    Kopp I, Bartsch D, Wild A et al (2001) Predictive genetic screening and clinical findings in multiple endocrine neoplasia type 1 families. World J Surg 25:610–616PubMedCrossRefGoogle Scholar
  19. 19.
    Marini F, Falchetti A, Del Monte F et al (2006) Multiple endocrine neoplasia type 2 Orphanet J Rare Dis 1:45PubMedCrossRefGoogle Scholar
  20. 20.
    Lairmore TC, Wells SA Jr, Moley Jeffrey F (2003) Sindromi da neoplasie multiendocrine. In: Sabiston (ed) Trattato di chirurgia. Le basi biologiche della moderna pratica chirurgica, prima edizione italiana sulla sedicesima americana. Antonio Delfino Editore, Rome, pp 697–707Google Scholar
  21. 21.
    Robson ME (2002) Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer cancer control. Cancer Control 9:457–465PubMedGoogle Scholar
  22. 22.
    Botkin JR, Smith KR, Croyle RT et al (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet 118A:201–209CrossRefPubMedGoogle Scholar
  23. 23.
    Schmeler KM, Sun CC, Bodurka DC et al (2006) Prophylactic bilateral salpingooophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108:515–520PubMedGoogle Scholar
  24. 24.
    Jacobs IJ, Skates SJ, MacDonald N et al (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353:1207–1210PubMedCrossRefGoogle Scholar
  25. 25.
    van Nagell JR Jr, DePriest PD, Reedy MB et al (2000) The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77:350–356PubMedCrossRefGoogle Scholar
  26. 26.
    Vasen HF, van der Luijt RB, Slors JF et al (1996) Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 348(9025):433–435PubMedCrossRefGoogle Scholar
  27. 27.
    Nugent KP, Philips RKS (1992) Rectal cancer risk in older patients with familial adenomatous polyposis and an ileorectal anastomosis: a cause for concern. Br J Surg 79:1204–1206PubMedCrossRefGoogle Scholar
  28. 28.
    Renda A, Izzo P, D’Armeinto F et al (2004) Chirurgia oncologica “Dna-guidata”. Archivio e Atti SIC, vol. 1. Pozzi, Rome, pp 141–172Google Scholar
  29. 29.
    Church JM (1995) The ileal pouch-anal anastomosis in challenging patients: stretching the limits. Aust N Z J Surg 65(2): 104–106PubMedCrossRefGoogle Scholar
  30. 30.
    Huls G, Koornstra JJ, Kleibeuker JH (2003) Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362(9379):230–232PubMedCrossRefGoogle Scholar
  31. 31.
    Sandler RS, Halabi S, Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(10):883–890PubMedCrossRefGoogle Scholar
  32. 32.
    Waddell WR, Loughry RW (1983) Sulindac for polyposis of the colon. J Surg Oncol 24(1):83–87PubMedCrossRefGoogle Scholar
  33. 33.
    Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316PubMedCrossRefGoogle Scholar
  34. 34.
    Giardiello FM, Yang VW, Hylind LM et al (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054–1059PubMedCrossRefGoogle Scholar
  35. 35.
    Annie Yu HJ, Lin KM, Ota DM et al (2003) Hereditary nonpolyposis colorectal cancer: preventive management. Cancer Treat Rev 29(6):461–470PubMedCrossRefGoogle Scholar
  36. 36.
    Karnes WE Jr, Shattuck-Brandt R, Burgart LJ et al (1998) Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 58:5473–5477PubMedGoogle Scholar
  37. 37.
    Sinicrope FA, Lemoine M, Xi L et al (1999) Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 117:350–358PubMedCrossRefGoogle Scholar
  38. 38.
    Toledo SPA, Cortina MA, Toledo RA, Lourenço DM (2006) Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics 61(1):59–70PubMedCrossRefGoogle Scholar
  39. 39.
    Cohen MS, Moley JF (2003) Surgical treatment of medullary thyroid carcinoma. J Intern Med 253:616–626PubMedCrossRefGoogle Scholar
  40. 40.
    Modigliani E, Coben R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 48:265–273CrossRefGoogle Scholar
  41. 41.
    Gill JR, Reyes-Mugica M, Iyengar S et al (1996) Early presentation of metastatic medullary cancer on multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 129:459–464PubMedCrossRefGoogle Scholar
  42. 42.
    Stjernholm MR, Freudenbourg JC, Mooney HS et al (1980) Medullary carcinoma of the thyroid before age 2 years. J Clin Endocrinol Metab 51:252–253PubMedCrossRefGoogle Scholar
  43. 43.
    Kaufman FR, Roe TF, Isaacs Jr H, Weitzman JJ (1982) Metastatic medullary thyroid carcinoma in young children with mucosal neuroma syndrome. Pediatrics 70:263–267PubMedGoogle Scholar
  44. 44.
    Samaan NA, Draznin MB, Halpin RE et al (1991) Multiple endocrine syndrome type IIb in early childhood. Cancer 68:1832–1834PubMedCrossRefGoogle Scholar
  45. 45.
    Skinner MA, DeBenedetti MK, Moley JF et al (1996) Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 31:177–181PubMedCrossRefGoogle Scholar
  46. 46.
    Smith VV, Eng C, Milla PJ (1999) Intestinal ganglioneuromatosis and multiple endocrine neoplasia type 2B: implications for treatment. Gut 45:143–146PubMedCrossRefGoogle Scholar
  47. 47.
    Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671PubMedCrossRefGoogle Scholar
  48. 48.
    Lerman C, Hughes C, Croyle RT et al (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75–80PubMedCrossRefGoogle Scholar
  49. 49.
    Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6): 1055–1062PubMedCrossRefGoogle Scholar
  50. 50.
    Kauf ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615CrossRefGoogle Scholar
  51. 51.
    Olivier RI (2004) Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90(8):1492–1497PubMedCrossRefGoogle Scholar
  52. 52.
    Iglehart JD, Kaelin CM (2003) Malattie della mammella. In: Sabiston (ed) Trattato di chirurgia. Le basi biologiche della moderna pratica chirurgica, prima edizione italiana sulla sedicesima americana. Antonio Delfino Editore, Rome, pp 555–590Google Scholar
  53. 53.
    Burke W, Daly M, Garber J et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997–1003PubMedCrossRefGoogle Scholar
  54. 54.
    Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84PubMedCrossRefGoogle Scholar
  55. 55.
    Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 93:1633–1637PubMedCrossRefGoogle Scholar
  56. 56.
    Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164PubMedCrossRefGoogle Scholar
  57. 57.
    Hartmann LC, Degnim A, Schaid DJ (2004) Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol 22(6):981–983PubMedCrossRefGoogle Scholar
  58. 58.
    Julian-Reynier CM, Bouchard LJ, Evans DG et al (2001) Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 15:959–968CrossRefGoogle Scholar
  59. 59.
    Renda A, Romano G, Carlomagno N et al (1992) Il follow-up degli operati per poliposi familiare del colon. Atti della SIC, vol. 3. Pozza, Rome, pp 229–252Google Scholar
  60. 60.
    Lynch HT, Lynch JF (2000) Hereditary nonpolyposis colorectal cancer. Semin Surg Oncol 18(4):305–313PubMedCrossRefGoogle Scholar
  61. 61.
    Rodriguez-Bigas MA, Vasen HF, Pekka-Mecklin J et al (1997) Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. Ann Surg 225:202–207PubMedCrossRefGoogle Scholar
  62. 62.
    Hahn M, Saeger HD, Schackert HK (1999) Hereditary colorectal cancer: clinical consequences of predictive molecular testing. Int J Colorectal Dis 14:184–193PubMedCrossRefGoogle Scholar
  63. 63.
    Weber T (1996) Clinical surveillance recommendations adopted for HNPCC. Lancet 348:465CrossRefGoogle Scholar
  64. 64.
    National Comprehensive Cancer Network (2003) Clinical practice guidelines in oncology. Available at: www.nccn.orgGoogle Scholar
  65. 65.
    Del Vecchio Blanco C, Renda A (1999) Il trattamento dei tumori del colon-retto. Conferenza Regionale Campana. Giuseppe de Nicola Editore, NaplesGoogle Scholar
  66. 66.
    Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261–269PubMedCrossRefGoogle Scholar
  67. 67.
    Jimenez C, Gagel RF (2004) Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2) Growth Horm IGF Re, 14(Suppl A):S150–S157CrossRefGoogle Scholar
  68. 68.
    Eccles DM (2004) Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. Ann Oncol 15(Suppl 4): iv133–iv138PubMedGoogle Scholar
  69. 69.
    Elit L (2001) Familial ovarian cancer. Can Fam Physician 47:778–784PubMedGoogle Scholar
  70. 70.
    Eisinger F (1998) Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee. Ann Oncol 9:939–950PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Nicola Carlomagno
    • 1
  • Luigi Pelosio
    • 1
  • Akbar Jamshidi
    • 1
  • Francesca Duraturo
    • 2
  • Paola Izzo
    • 2
  • Andrea Renda
    • 1
  1. 1.Surgical, Anesthesiology-rianimative and Emergency Sciences DepartmentFederico II UniversityNaplesItaly
  2. 2.Department of Biochemistry and Biomedical TechnologiesFederico II UniversityNaplesItaly

Personalised recommendations